Croucher PJP, Ridinger M, Becker PS, Lin TL, et al. Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia. Ann Hematol 2023 Sep 13. doi: 10.1007/s00277-023-05442.
PMID: 37702821